LOGIN
Reduction of factor XI levels in TKA patients safe and effective for VTE prevention
April 2015
Reduction of factor XI levels in TKA patients safe and effective for VTE prevention
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Factor XI antisense oligonucleotide for prevention of venous thrombosis
N Engl J Med. 2015 Jan 15;372(3):232-40.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
300 patients scheduled for total knee arthroplasty (TKA) were randomized to receive Factor XI Antisense Oligonucleotide (FXI-ASO) 200 mg, FXI-ASO 300 mg, or enoxaparin 40 mg. This was done to evaluate the safety and efficacy of FXI-ASO in the reduction of risk of venous thromboembolism (VTE) in patients following surgery. Patient outcomes were measured through venography at day 10 +/- 2, to determ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.